glp-1 nafld Resolution of NASH and hepatic fibrosis by the GLP-1R and GCGR dual-agonist cotadutide via modulating mitochondrial function and lipogenesis Therapeutic Approach to NAFLD-NASH |

Among 8,184 adults without diabetes who initiated injectable semaglutide or tirzepatide for obesity, 4,492 had a dispensing gap longer than 90 days within the first year

W.BlauwG

22 Even worse, those bare GOx-mediated mineralized cores (GMCs) with no targeting system lacked the capability to specifically aggregate within tumor cells, which made the unsealed delivery systems potential risks to normal tissues

PFK-deficient red blood cells display a metabolic block at the PFK step in glycolysis and have decreased concentrations of 2,3-bisphosphoglyceric acid (2,3-BPG, also called 2,3-diphosphoglyceric acid, 2,3-DPG

Carniol: Minimally Invasive and Office-Based Procedures in Facial Plastic Surgery